GLP-1 receptor activation studied for effects on glucose-dependent insulin signaling, glucagon pathways, and gastric emptying parameters in research models cAMP-mediated signaling GLP-1R activation increases intracellular cAMP, activating PKA and EPAC pathways examined in preclinical signaling studies Central nervous system receptor research GLP-1 receptors are expressed in hypothalamic regions studied in energy homeostasis and appetite-regulation research Albumin binding via C-18 chain the fatty acid modification enables non-covalent albumin binding, supporting pharmacokinetic and clearance studies in laboratory settings As a single GLP-1 receptor agonist, semaglutide is commonly used as a reference compound for GLP-1R biology research, enabling direct comparison with dual agonists (tirzepatide) and triple agonists (retatrutide) to isolate GLP-1 receptor-specific effects
Updated by Dr Jessica Witherspoon, General Practice Registrar, Doctors Grand Plaza, Brisbane, QLD, Australia
A year after stopping taking glucagon-like peptide 1 (GLP-1) receptor agonists like semaglutide (WeGovy) and tirzepatide (Mounjaro) people regain on average 60% of their lost weight, the latest analysis found
Rapid weight loss from GLP-1 medications like Ozempic can lead to muscle loss alongside fat, but there are effective ways to preserve your strength
A 2022 systematic review of randomized controlled trials confirms its effectiveness in improving signs of photoaging, including fine wrinkles, skin texture, and collagen formation
Between 1961 and 1985 the average weekly consumption of fresh fruit, green vegetables, potatoes, fresh fish and red meat was reduced in Britain